Engflag

Dr-Koff

Quick links to important sections

Dr-Koff

Dr-Koff_PL

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dr-Koff

Property Description
Active Ingredients Bromhexine Hydrochloride, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide, Guaifenesin
Form Oral Solution or Syrup
Pharmacological Class Antitussive, Expectorant, Mucolytic, and Antihistamine Combination
General Purpose Symptomatic relief of cough, chest congestion, and allergy symptoms
Origin Synthetic/Derived

Dr-Koff: Classification and Core Identity

Dr-Koff is a fixed-dose combination drug classified as an Antitussive, Expectorant, Mucolytic, and Antihistamine agent, typically presented as an oral solution or syrup. This multi-component identity is designed for the comprehensive, simultaneous management of symptoms associated with respiratory tract irritation. The product's structure, combining four distinct pharmacological actions, is a common strategy in symptomatic therapy for cold and cough relief.

Composition and Multi-Component Profile

The formulation relies on four separate synthetic active ingredients of pharmaceutical grade. These components include the cough suppressant Dextromethorphan Hydrobromide, the expectorant Guaifenesin, the secretolytic agent Bromhexine Hydrochloride, and the first-generation antihistamine, Chlorpheniramine Maleate. This multi-ingredient structure allows the medication to act on both the central cough reflex and the peripheral issues of phlegm and allergic response. For example, Bromhexine's targeted mucolytic action reduces the viscosity of bronchial secretions, acting to make thick mucus easier to clear.

General Purpose and Symptomatic Focus

The general purpose of Dr-Koff is the systematic alleviation of respiratory discomfort caused by concurrent symptoms, such as an irritating cough, the presence of thick phlegm, and nasal symptoms related to histamine release. By integrating an antitussive, two mucus-modifying agents, and an antihistamine, the formulation aims to manage the irritation and congestion that commonly accompany upper respiratory issues, facilitating overall symptomatic improvement.

What side effects are possible with Dr-Koff?

The possible side effects and safety characteristics of Dr-Koff are determined by the regulatory documentation for its four active components, reflecting classifications by frequency and affected body systems.

Adverse Reaction Scope

Adverse effects are categorized by the systems involved, as documented in official labeling. The most Common effects are generally related to the Nervous System and Gastrointestinal Tract, while rare but Serious Adverse Reactions are also explicitly listed.

Classification Affected System / Effect Key Characteristics (Regulatory Classification)
Common Effects Nervous System Disorders Drowsiness, sedation, or somnolence.
Gastrointestinal Disorders Nausea, vomiting, or abdominal discomfort.
Uncommon Effects Skin and Subcutaneous Tissue Rash or urticaria (hives).
Anticholinergic Effects Dry mouth, nose, or throat, and dizziness.
Serious Reactions Immune/Skin Disorders Rare potential for Anaphylactic Reactions and Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS).

Safety Constraints and Special Populations

Official regulatory documents define specific limitations on use and population-specific considerations:

  • Mandated Restriction: The medicine is contraindicated for concurrent use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing such therapy, due to the risk of serious adverse events.
  • CNS Depressants: A constraint exists regarding the concurrent use of the drug with alcohol or other CNS depressants, which can intensify sedative effects.
  • Older Adults: Regulatory text notes that older adults may exhibit increased sensitivity to anticholinergic effects, potentially leading to pronounced sedation or confusion, requiring careful consideration of the safety profile.

Overdose and Emergency Response

The official regulatory profile for Dr-Koff overdose is defined by the known toxicity of its active components, which can lead to serious, multi-systemic effects. The regulatory mandate is clear: seek immediate medical attention and contact emergency services immediately upon suspected overdose.

Overdose scope

Domain Official Regulatory Statements
Documented overdose presentations Manifestations involve CNS effects like somnolence, agitation, ataxia, psychosis, and nystagmus. Anticholinergic signs, such as fixed and dilated pupils and flushed face, are also documented, alongside nausea and vomiting.
Physiological systems affected Primarily the Central Nervous System, the Cardiovascular System (arrhythmias, hypotension, tachycardia), and the Respiratory System (respiratory depression, apnoea).
Population-specific overdose notes Official labeling notes that children and the elderly are more susceptible to severe neurological anticholinergic effects and paradoxical CNS excitation.

Overdose classifications (high-level)

Classification Official Regulatory Statements
Severity classification Classified as having the potential for severe or life-threatening outcomes, including convulsions, coma, and the risk of Serotonin Syndrome.
Overdose-context constraints No specific antidote is known for the combination product. Management must include symptomatic and supportive treatment and continuous monitoring of cardiac and respiratory function.

Resulting overdose structure

Official overdose statements:

  • The potential for Serotonin Syndrome is documented as a risk of overdose.
  • Immediate medical attention is the mandatory action required by regulatory authorities.
  • Supportive procedures detailed include administering activated charcoal and component-specific interventions such as Naloxone for respiratory depression or anticonvulsants for seizures.

Connection to the overall overdose profile: Regulatory documents establish that the spectrum of symptoms, from anticholinergic signs to severe CNS depression, necessitates the immediate contact with emergency services as the non-negotiable threshold for intervention. The official profile details the toxicity and the requirements for urgent professional assessment and standardized supportive care.

Therapeutic Uses of Dr-Koff

Dr-Koff is commonly used to help with symptomatic relief in acute settings, applied in scenarios where symptoms cluster into patterns requiring supportive management. It addresses symptoms that create noticeable functional strain, offering support during temporary episodes of discomfort. Such formulations are designed for the combined management of the common cold, cough, and allergy symptoms.

The medication is relevant for easing symptoms related to an irritating cough, chest heaviness, and viscous chest secretions, as well as common allergic discomforts like sneezing, runny nose (rhinorrhea), and watery, itchy eyes. It is generally applied in settings marked by the discomfort of acute viral upper respiratory illnesses, such as the common cold and flu, providing support when short-term symptomatic assistance is needed.

The supportive action contributes to improved day-to-day comfort and may assist with maintaining functional stability during symptomatic phases. The combination is applied in addressing symptoms related to heightened physiological activity and multiple concurrent symptoms. This helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Use in Conditions with Concurrent Symptoms

Dr-Koff is commonly used across conditions presenting with acute episodes where multiple symptoms occur together, which helps manage distressing symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dr-Koff?

Dr-Koff’s official eligibility is defined by the absolute contraindications and restrictions associated with its multiple components, as documented in regulatory guidelines. The medicine is typically approved for use in adults and adolescents aged 12 years and older. Use in children 6 to under 12 years is conditional.

Prohibited Populations and Conditions

Official regulatory documents state that Dr-Koff is contraindicated in children under 4 years of age and in patients who are currently taking or have recently stopped a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.

The medicine is also prohibited for individuals with known hypersensitivity to any of the four active ingredients. Contraindications related to pre-existing conditions include narrow-angle glaucoma, conditions causing urinary retention, and severe liver or kidney disease.

Age and Physiological Restrictions

Older adults (60 years and older) should use the product with caution. The official label restricts use during reproductive periods: it is not recommended for breastfeeding mothers. Use during pregnancy is permitted only if clearly needed and requires consultation with a health professional. Caution is also advised for patients with a persistent cough or pre-existing asthma.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented drug-drug interactions based on authoritative regulatory documents for the active ingredients commonly found in this product class.

Significant Drug Interactions

Interacting Product Category Regulatory Constraint Interaction Rationale (Official)
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated: Do not use with, or within 14 days of stopping, an MAOI. Risk of serious, potentially fatal reactions, including changes in mental status, high body temperature, and muscle rigidity.
Central Nervous System (CNS) Depressants Avoid Use: Use with caution; monitor closely if co-administration is necessary. Increased risk of enhanced sedation, dizziness, and impairment, stemming from an additive depressant effect.
Alcohol Avoid Use: Concurrent consumption is strongly discouraged. Potentiation of CNS depressant effects, leading to increased drowsiness and motor impairment.

Official Regulatory Notes

The co-administration of this product with Monoamine Oxidase Inhibitors (including medicines like phenelzine or tranylcypromine) is strictly prohibited across regulatory jurisdictions due to the severe, life-threatening nature of the resulting interaction. This constraint mandates a 14-day washout period after MAOI therapy is discontinued before this product may be started. Concomitant use with alcohol and other CNS depressants (such as tranquilizers or sedatives) is subject to warnings related to additive effects on the central nervous system. These documented constraints define the primary structure of this product's interaction profile.

Mechanism of Action

How Dr-Koff Works: Mechanism of Action

Dr-Koff utilizes two complementary pharmacodynamic mechanisms to modulate the cough reflex arc and influence the rheological properties of tracheobronchial secretions.

Central Cough Reflex Modulation

This mechanism involves Dextromethorphan (DM) engaging the Central Nervous System (CNS). DM functions as an agonist at the Sigma-1 (sigma1) receptor and an antagonist at the NMDA receptor within the medullary cough center of the brainstem. This mechanistic cascade decreases the frequency of efferent motor signaling, resulting in a higher threshold for cough reflex initiation. This central modulation shapes the drug's overall physiological effect by limiting the initiation of the motor response.

Respiratory Secretion Viscosity and Clearance

This mechanism focuses on the expectorant effect of Guaifenesin (GF), which modulates the physical properties of respiratory secretions. The interaction involves stimulating gastric mucosal receptors, triggering a gastro-pulmonary reflex that increases bronchial gland secretion. This action reduces the viscosity and increases the volume of tracheobronchial mucus, thereby enhancing the physiological process of mucociliary clearance. The modification of secretory viscosity and volume facilitates the expulsion of tracheobronchial material during expiration, affecting the rheology of the airways.

Dosage and Administration Information

Official Administration Protocol for Dr-Koff

Dr-Koff is a four-component oral solution/syrup whose use is governed by principles established for cough, cold, and allergy combination products. The administration focuses on accurate, time-bound oral intake, adhering to strict volume and frequency constraints.

Administration Scope

Feature Guideline
Route of administration Oral administration as a liquid solution or syrup.
Dosing schedule (Adults ge 12 years) A standard single dose volume (e.g., 20 mL) must be measured.
Timing in relation to meals May be taken with or without food.
Preparation requirements The container must be shaken well before each use.

Frequency, Duration, and Special Conditions

Classification Administration Rule
Frequency pattern Dosing occurs at intervals of every 4 hours or every 6 hours.
Maximum Use Limit Administration must not exceed 4 to 6 doses in a 24 hour period, as designated on the product label.
Age-group administration rules The product is generally not for use in children under 4 years; lower, age-specific volumes are designated for older pediatric patients.
Procedural condition The provided dosing cup or device must be used for measuring the volume.
Course duration Intended for short-term, temporary use; guidelines recommend discontinuing use if symptoms persist beyond 7 days.

The official protocol dictates a precise sequence: shaking the container, using the dedicated measuring device for the correct volume, and ensuring strict adherence to the minimum time interval between administrations. This procedural structure is intended for all users to follow established guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dr-Koff

The research landscape for Dr-Koff reflects the regulatory status of its individual components established for use in treating specific symptoms in the context of over-the-counter (OTC) monographs. Scientific understanding is primarily derived from studies examining the single agents, with less data available for this specific four-ingredient combination.

Evidence for Symptomatic Management of Acute Cough

Research examined how the cough-suppressant (Dextromethorphan) and expectorant (Guaifenesin) components are used in research exploring how symptoms change over time in individuals with acute cough associated with the common cold. The evidence predominantly comes from short-term Randomized Controlled Trials (RCTs) comparing the individual active components against a placebo. Findings were often mixed and variable across systematic reviews. Overall, the available evidence on the data patterns related to individual antitussives and expectorants for acute cough in adults shows variability and limited consistency. Research on the data patterns related to the 4-component combination has not been extensively characterized, and existing research provides limited insight into long-term outcomes.

Research on Productive Cough and Viscous Chest Secretions

Research on the mucus-modifying agents (Bromhexine and Guaifenesin) was studied for its application in conditions associated with acute or disruptive episodes where thick phlegm is present. Outcomes measured included objective changes in sputum characteristics and patient-reported outcomes describing perceived discomfort. The scientific findings regarding the clinical relevance of the measured changes in acute, self-limiting viral illness remains an area of research discussion.

Evidence for Managing Concurrent Allergy Symptoms

Research for the antihistamine component (Chlorpheniramine) used in studies examining symptom intensity or variability in conditions characterized by fluctuating or episodic manifestations. The evidence for this component is often associated with a more numerous body of research in trials exploring specific histamine-mediated symptoms. It remains uncertain how the profile of the antihistamine may be modified when it is delivered in this fixed combination, as comparative evidence is lacking for this precise four-way drug product.

Frequently Asked Questions (FAQ)

Common questions about Dr-Koff (FAQ)

Q: What is the exact dose for an adult 18 years old?

According to official product information, the standard single dose for adults and adolescents 12 years of age and older is typically a specific volume, such as 20 mL. This dose is designated for administration every 4 to 6 hours on the product label. Regulatory guidelines emphasize the importance of using the provided measuring device and strictly adhering to the instructions printed on the label.

Q: Can I give Dr-Koff to my 5-year-old child?

Regulatory documents state that this medicine is generally not recommended for children under 4 years of age. For children between 4 and 12 years old, official guidelines designate lower, age-specific volumes. Official guidelines recommend consulting with a health professional to determine the appropriate use and volume for children in this age group.

Q: Do I need to shake the bottle before measuring the dose?

Official regulatory guidelines state that the container should be shaken well before each use. Shaking the bottle helps to ensure the active ingredients, which may separate over time, are evenly distributed throughout the solution before the dose is measured. This procedure is key to proper administration.

Q: How long is it safe to use Dr-Koff?

This medicine is intended for short-term and temporary management of symptoms. Official product labels advise users to discontinue use if symptoms persist or worsen for more than 7 days. If symptoms continue past this period, it is recommended to seek professional medical review.

Q: What should I do if I miss a dose of Dr-Koff?

General drug administration guidance indicates that if a scheduled dose is missed, it is typically taken as soon as it is remembered. If it is nearly time for the next dose, the usual regulatory guidance is to skip the missed dose and resume the regular schedule. Taking a double dose to compensate for the missed one is generally advised against.

Q: Can I mix Dr-Koff with juice or water to make it easier to swallow?

While some liquid medicines may be mixed with small amounts of liquid or soft food, this is not specifically detailed in the primary regulatory warnings for Dr-Koff. It is recommended to confirm with a pharmacist or health professional before mixing the solution with juice or water to ensure that the medicine's effectiveness and stability are maintained.

Q: What should I do if I take too much Dr-Koff (overdose)?

The official product labeling contains an explicit, mandatory warning regarding accidental overdose. This warning advises users to stop use and seek professional medical help, or contact a Poison Control Center, right away. This is a critical safety instruction.

How should Dr-Koff be stored and disposed of?

The official storage and disposal guidelines for Dr-Koff (Bromhexine HCl, Chlorpheniramine Maleate, Dextromethorphan HBr, Guaifenesin Oral Solution/Syrup) are defined by the regulatory authorities.

Storage & Disposal Scope

Scope Item Official Regulatory Requirement
Labeled storage temperature requirements Store at Controlled Room Temperature ( CRT), generally between 20 C and 25 C (68 F to 77 F).
Light/moisture protection requirements Protect from light and store away from moisture; do not store in the bathroom.
Handling requirements Do not freeze the oral solution; do not refrigerate unless specifically stated on the label.
Child-protection storage requirements Keep out of the sight and reach of children (a mandatory safety requirement).
Disposal instructions Dispose of unused or expired product via a drug take-back program or by following household disposal guidelines for non-Flush List medicines. Do not flush down the toilet or pour down the sink.

Connection to the overall storage/disposal profile: Regulatory documents mandate that the oral solution must be kept in its original, tightly closed container at Controlled Room Temperature to maintain the stability of the active ingredients until the expiration date. These instructions are essential for product preservation and safe discard, ensuring the medicine is kept out of the reach of children and prevents environmental contamination through wastewater disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dr-Koff found in:

A-Z Index: